WO2011141431A1 - Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation - Google Patents

Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation Download PDF

Info

Publication number
WO2011141431A1
WO2011141431A1 PCT/EP2011/057438 EP2011057438W WO2011141431A1 WO 2011141431 A1 WO2011141431 A1 WO 2011141431A1 EP 2011057438 W EP2011057438 W EP 2011057438W WO 2011141431 A1 WO2011141431 A1 WO 2011141431A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
angiotensin
febuxostat
acceptable salts
xanthine oxidase
Prior art date
Application number
PCT/EP2011/057438
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini International Operations Luxembourg S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011141431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ603414A priority Critical patent/NZ603414A/en
Priority to MX2012013054A priority patent/MX2012013054A/es
Priority to US13/697,066 priority patent/US20130131128A1/en
Priority to CN2011800232573A priority patent/CN103037861A/zh
Priority to KR1020127032188A priority patent/KR20130101447A/ko
Priority to BR112012028887A priority patent/BR112012028887A2/pt
Priority to AU2011252151A priority patent/AU2011252151A1/en
Priority to EP11718734.4A priority patent/EP2568982B1/fr
Priority to SG2012082319A priority patent/SG185474A1/en
Priority to JP2013509533A priority patent/JP2013526503A/ja
Application filed by Menarini International Operations Luxembourg S.A. filed Critical Menarini International Operations Luxembourg S.A.
Priority to EA201201528A priority patent/EA201201528A1/ru
Priority to MA35430A priority patent/MA34297B1/fr
Priority to CA2798573A priority patent/CA2798573A1/fr
Publication of WO2011141431A1 publication Critical patent/WO2011141431A1/fr
Priority to IL222927A priority patent/IL222927A0/en
Priority to ZA2012/09295A priority patent/ZA201209295B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to an association of active principles, i.e. of a xanthine oxidase inhibitor with one or more angiotensin II receptor antagonists, pharmaceutical compositions comprising said active principles, for use in a therapeutic treatment in humans or animals, and methods for the preparation thereof.
  • active principles i.e. of a xanthine oxidase inhibitor with one or more angiotensin II receptor antagonists
  • pharmaceutical compositions comprising said active principles, for use in a therapeutic treatment in humans or animals, and methods for the preparation thereof.
  • Such associations and such compositions proved particularly effective in the treatment of hypertension, alone or in association with hyperuricemia and/or hyperglycemia or to other disorders in the clinical context of the metabolic syndrome.
  • Gout is an invalidating chronic disease characterized by hyperuricemia and deposition of monosodium urate crystals in various tissues, mainly at the joint level and in the kidney. Hyperuricemia and gout are frequently associated to other cardiovascular risk factors such as hypertension and other elements that are part of the metabolic syndrome, like obesity, fasting hyperglycemia, low HDL levels and high triglyceride levels.
  • a xanthine oxidase inhibitor well-known in the literature is allopurinol. More recently, other xanthine oxidase inhibitors have appeared on the market; among them, febuxostat is of particular relevance.
  • Febuxostat is a powerful non-purine selective inhibitor of xanthine oxidase which in clinical studies has been shown to reduce hyperuricemia more effectively than allopurinol.
  • Febuxostat is a thiazole derivative having formula (I), belonging to the class of xanthine oxidase inhibitors, and was originally described in EP513379.
  • EP1020454 it is also described a polymorphic form of febuxostat and a process for obtaining it.
  • WO2004060489 it is described the use of xanthine oxidase inhibitors for increasing cardiac contractility in CHF (Chronic Heart Failure) patients.
  • febuxostat is used to reduce the QT interval in patients in which such interval is prolonged, and in the pathologies associated thereto.
  • WO200806401 5 the use of xanthine oxidase, among which febuxostat, is indicated to preserve renal function.
  • xanthine oxidase inhibitors among which febuxostat, preferably for the treatment of prehypertension characterized by systolic pressure between 120 and 139 mmHg and diastolic pressure between 80 and 89 mmHg; here, xanthine oxidase inhibitors seem to be indicated also in the treatment of more marked hypertensions, though results obtained do not seem to be equal to those of already known anti-hypertensive agents.
  • angiotensin I I receptor antagonists must be considered of particular relevance; compounds known as 'sartans', commonly used in clinical practice and represented by the compounds selected from the group of: candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and valsartan.
  • Sartans act by blocking the angiotensin II AT1 receptor, a peptide controlling vascular tone and sodium reabsorption, i.e., blocking the hypertensive effect of angiotensin I I.
  • EP1336407 EP1 604664, associations between olmesartan medoxil and hydrochlorotiazide or amlodipine are claimed.
  • the present invention is based on the surprising discovery made by the Inventors that the association of a non-purine xanthine oxidase inhibitor, in particular febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof in combination with one or more angiotensin I I receptor antagonists or pharmaceutically acceptable salts thereof exhibits a synergistic therapeutic effect in the treatment of hypertension.
  • a non-purine xanthine oxidase inhibitor in particular febuxostat
  • pharmaceutically acceptable salts thereof or polymorphic forms thereof in combination with one or more angiotensin I I receptor antagonists or pharmaceutically acceptable salts thereof exhibits a synergistic therapeutic effect in the treatment of hypertension.
  • experimental data reported in the present description demonstrate that the therapeutic effect resulting from the association of the two active principles is greater than the sum of the therapeutic effects resulting from the same dosages of each active principle administered alone.
  • a first object of the present invention is an association of the active principles:
  • a second object of the present invention is a pharmaceutical composition comprising, as active principle, a mixture of:
  • xanthine oxidase inhibitor febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof;
  • one or more carriers and/or diluents and/or pharmaceutically acceptable excipients for use in a human or veterinary therapeutic treatment.
  • Another object of the present invention is a method for the preparation of the composition according to the present description, wherein the active mixture comprising:
  • one or more angiotensin I I receptor antagonists or pharmaceutically acceptable salts thereof is formulated in suitable dosage units with one or more carriers and/or diluents and/or pharmaceutically acceptable excipients.
  • the present invention advantageously entails a greater anti-hypertensive activity compared to that observed by using the sole angiotensin I I receptor antagonists or the sole xanthine oxidase inhibitor. Moreover, a further advantage is given by the possibility of obtaining significant effects in the treatment of hypertension with a reduced amount of angiotensin I I receptor antagonist with respect to the monotherapy treatment.
  • the present invention relates to an association of the active principles:
  • association in the present description it is meant an association of the active principles, both in the form of a physical mixture constituted by said active principles in a single dosage unit and in the form of dosage units physically separated for each active principle, but intended for a concomitant administration. In both cases, association must ensure a synergy of the therapeutic effects obtained from the individual active principles with respect to the effect obtained in monotherapy.
  • the non-purine xanthine oxidase inhibitor of said association is preferably febuxostat, a thiazole derivative having formula (I), or pharmaceutically acceptable salts thereof or polymorphic forms thereof.
  • Pharmaceutically acceptable salts of xanthine oxidase inhibitors, and in particular of febuxostat include but are not limited to cations of alkali metals and of alkaline earth metals, such as lithium, sodium, potassium, calcium, magnesium or aluminium salts, or non-toxic derivatives with quaternary ammonium and cations of amines such as ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, or derive from the addition of organic amines such as ethylendiamine, ethanolamine, diethanolamine, piperazine, tromethamine, lysine, arginine and the like.
  • Febuxostat its salts or polymorphic forms thereof could be obtained or prepared according to methods described in the known art, like e.g. in EP513379.
  • Polymorphic forms of febuxostat include, but are not limited to the forms described in European Patent EP1 020454.
  • the angiotensin I I receptor antagonists are selected from the group comprising olmesartan medoximil, candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan or pharmaceutically acceptable salts thereof.
  • the angiotensin I I receptor antagonists may be chiral or non- chiral, or specific polymorphic forms thereof.
  • chiral molecules a single enantiomer, a mixture of enantiomers or diastereoisomers or the racemic mixture could be used.
  • those specific stereoisomers, as well as polymorphic forms, which exhibit a greater biological activity are to be preferred.
  • compositions of angiotensin II receptor antagonists (sartans) having an acid function in the molecule include but are not limited to cations of alkali metals and of alkaline earth metals, such as lithium, sodium, potassium, calcium, magnesium or aluminium salts, or non-toxic derivatives with quaternary ammonium and cations of amines such as ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, or derive from the addition of organic amines such as ethylendiamine, ethanolamine, diethanolamine, piperazine, tromethamine, lysine, arginine and the like.
  • alkali metals and of alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium or aluminium salts
  • non-toxic derivatives with quaternary ammonium and cations of amines such as ammonium, tetramethylammonium
  • said angiotensin II receptor antagonist is olmesartan medoximil or a pharmaceutically acceptable salt thereof.
  • the xanthine oxidase inhibitor, febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof are associated with one or more of said angiotensin I I receptor antagonists or pharmaceutically acceptable salts thereof in a weight ratio of febuxostat/angiotensin II receptor antagonists comprised between 0.1 and 200, or better between 0.6 and 10.
  • febuxostat in an amount comprised between 1 0-200 mg, or better comprised between 25-120 mg, in association with an amount of angiotensin II receptor antagonists comprised between 1 -100 mg, e.g. comprised between 10-40 mg.
  • a further embodiment of the present invention relates to pharmaceutical compositions comprising, as active principle, a mixture of:
  • xanthine oxidase inhibitor febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof;
  • angiotensin II receptor antagonists or pharmaceutically acceptable salts thereof b) one or more angiotensin II receptor antagonists or pharmaceutically acceptable salts thereof, and one or more usual pharmaceutically acceptable excipients, additives and/or diluents, for use in a human or veterinary therapeutic treatment.
  • the angiotensin II receptor antagonist or the angiotensin II receptor antagonists to be used according to the above-described composition are selected from the group comprising: olmesartan medoximil, candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan or pharmaceutically acceptable salts thereof.
  • compositions according to the present invention may be formulated in various forms depending on the selected administration route.
  • Oral administration of solid forms my include forms such as capsules, tablets, pills, powders and granules.
  • the two active principles, the xanthine oxidase inhibitor and the anti-hypertensive agent can be mixed with one or more pharmaceutically acceptable inert excipients.
  • excipients may be selected among those commonly known in the state of the art and include, but are not limited to: a) carriers, such as sodium citrate and calcium phosphate, b) fillers, such as starch, lactose, microcrystalline cellulose, sucrose, glucose, mannitol and colloidal silica, c) moistening agents, such as glycerol, d) disintegrating agents, such as alginates, calcium carbonate, starches, derivatives of starch, of cellulose and polyvinylpyrrolidone, silicates and sodium carbonate, e) binders, such as carboxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, polymeric derivatives of cellulose, starch derivatives, f) retarding agents, such as paraffin, cellulose polymers, fatty acid esters, g) absorption accelerators, such as quaternary ammonium compounds, h) wetting agents and surfactants, such as cetyl alcohol and g
  • the excipients include but are not limited to compounds of the type: lactose, high molecular weight polyethylene glycol, and the like.
  • Solid-dosage forms may be coated with enteric, gastric coatings, or coatings of other type well-known in the state of the art. They may contain matting agents and may be of the type such as to allow the release of active ingredients only or preferably in a certain section of the intestine, optionally in a delayed manner. Substances capable of allowing such a delayed use include, but are not limited to polymers and waxes.
  • Liquid forms suitable for oral administration are emulsions, solutions, prepared or extemporary suspensions, syrups and elixirs.
  • Excipients suitable for the formulations according to the present invention in liquid forms for oral use include, but are not limited to diluents commonly used in the art, such as water or other solvents, solubilizing and emulsifying agents selected from ethyl alcohol, polyalcohols, propylene glycol, glycerol, polyethylene glycol and sorbitan esters.
  • These formulations can also contain sweeteners and aromas selected from those well-known in the state of the art.
  • compositions suitable for pharmaceutically acceptable parenteral injections may comprise sterile aqueous solutions, sterile dispersions, suspensions or emulsions or powders for a reconstitution in injectable solutions or dispersions; examples of excipients suitable therefor include, but are not limited to aqueous or non-aqueous carriers, diluents, solvents or vehicles selected from: water, ethanol, polyoils (propylene or polyethylene glycol, glycerol, and the like), polyalcohols, isopropyl alcohol, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 .3-butylene glycol, dimethylformamide, vegetable oils (in particular of olive, cotton, peanut, corn, wheat germ, olive, castor, sesame), organic esters such as ethyl oleate or the like.
  • excipients suitable therefor include, but are not limited to aqueous or non-aqueous carriers
  • compositions may also contain preservatives of antibacterial or antifungal type, selected, yet not exclusively, from: paraben, chlorbutanol, phenol, sorbic acid and the like. It may also be useful to include an isotonic agent, e.g., a sugar, sodium chloride or the like. Moreover, pharmaceutical forms with a delayed absorption may be obtained with agents such as, for instance, yet not exclusively, aluminium monostearate and gelatin.
  • the suspensions may contain suspending agents such as, for instance, yet not exclusively, ethoxylated isostearic alcohols, polyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium hydroxide, bentonite, alginates and cellulose derivatives in general or the like.
  • suspending agents such as, for instance, yet not exclusively, ethoxylated isostearic alcohols, polyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium hydroxide, bentonite, alginates and cellulose derivatives in general or the like.
  • the right fluidity can be maintained with a coating material such as lecithin, with the maintaining of the right particle sizes in the dispersions or with the use of surfactants.
  • slow-release formulations can be prepared, by the techniques and products well-known in the state of the art.
  • the associations and compositions of the present invention are extremely effective in the treatment, also meant as prophylaxis and therapy, of hypertension, in humans or animals.
  • hypotension that with diastolic values higher than ad 80 mm/Hg and/or systolic values higher than 120 mm/Hg.
  • Hypertension can be associated or not associated to other pathologies or symptoms.
  • the mixtures and compositions described herein are useful also in the therapeutic treatment of hypertension associated to hyperuricemia.
  • Symptoms such as hypertension and hyperuricemia can also be associated to specific pathologies like, e.g., the metabolic syndrome.
  • metabolic syndrome it is meant a clinical condition accompanied by manifestations such as obesity.
  • association and compositions described herein can therefore be used in the therapeutic treatment of hypertension associated to hyperuricemia and/or other disorders in the context of the metabolic syndrome.
  • Dosage may vary depending on the patient's age and general conditions, the nature and seriousness of the pathology or disorder and of the administration route and type. Dosage should therefore take into account the specific condition to be treated (e.g., hyperglycemia alone or in association with hyperuricemia), the severity of the condition to be treated, the age, weight and general physical conditions of the specific patient, as well as other drugs that the patient is taking, as is well-known to those skilled in the art. Moreover, it is evident that said effective amount may, when required, be lowered or raised according to the responses of the treated patient and/or according to the assessment of the physician prescribing the compounds of the present invention.
  • the specific condition to be treated e.g., hyperglycemia alone or in association with hyperuricemia
  • said effective amount may, when required, be lowered or raised according to the responses of the treated patient and/or according to the assessment of the physician prescribing the compounds of the present invention.
  • compositions preferably for oral use in solid form contain an amount of xanthine oxidase inhibitor, specifically febuxostat, of between 1 0 and 200 mg per dosage unit, and preferably of from 25 to 1 00 mg, and an amount of angiotensin I I receptor antagonist, preferably olmesartan medoximil, of between 1 and 100 or of between 1 0 and 40 mg per dosage unit.
  • xanthine oxidase inhibitor specifically febuxostat
  • angiotensin I I receptor antagonist preferably olmesartan medoximil
  • dosage unit in the present description it is meant the unitary formulation for a single administration, e.g. a tablet, capsule, etc.
  • unit dosage it is meant the amount of active principle for a single administration.
  • the pharmaceutical mixtures and compositions of the invention could be prepared according to techniques known in the field both using the previously prepared association of active principles, and mixing the individual compounds directly during the preparation of the composition.
  • association of active principles may be obtained by a step of mixing the xanthine oxidase inhibitor, febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof with one or more angiotensin II receptor antagonists or pharmaceutically acceptable salts thereof, in a weight ratio comprised between 0.5 and 400, or between 2.5 and 120.
  • the mixture of active principles is formulated in suitable dosage units with one or more pharmaceutically acceptable excipients and additives.
  • Systolic pressure was measured in non-anesthesized animals by means of a tail cuff sphygmomanometer (Blood Pressure Analysis System BP-2000, Visitech Systems, USA) equipped with an automatic system for data acquisition and processing.
  • Hyperuricemia was induced with administration of potassium oxonate (250 mg/kg IP, 2 hours after the last dose of drugs and 2 hours before the test), an uricase inhibitor capable of inducing experimental hyperuricemia.
  • Plasma levels of uric acid were measured with a standard colorimetric enzymatic method.
  • Febuxostat and/or olmesartan were administered orally once per day for 7 days, by gavage, at the doses of 1 -3-10 mg/kg.
  • SBP systolic pressure
  • uricemia plasma uric acid/urate levels
  • Basal values of plasma uric acid were comparable in all groups and comprised between 0.37 ⁇ 0.06 and 0.53 ⁇ 0.08 mg/dL. After one week of daily treatment with febuxostat and/or olmesartan, potassium oxonate administration produced a significant increase of plasma uric acid, higher than over 1 00% with respect to the basal value.
  • Febuxostat (1 -3-10 mg/kg per os, daily for 1 week) showed a slight inhibitory effect on systolic pressure.
  • Olmesartan medoxomil (1 -3-1 0 mg/kg per os, daily for a week) reduced systolic pressure in a dose-dependent manner (Table 1 ).
  • Combined administration of febuxostat and olmesartan medoxomil, at the dose of 3 mg/kg per os reduced the systolic pressure in spontaneously hypertensive rats to the values obtained with the dose of olmesartan medoxomil (10 mg/kg per os) showing consistent enhancement of the hypotensive effect of angiotensin I I AT1 receptor.
  • Table 1 Effect of daily oral administration for one week of febuxostat, olmesartan medoxomil or combination thereof on uricemia and systolic pressure values in spontaneously hypertensive rats (SHR).
  • Olmesartan 1 1.16+0.11 - 0.01 217+14 -22
  • Uricemia and systolic pressure values were recorded 4 hours after the last dose of drugs or vehicle.
  • Potassium oxonate 250 mg/kg IP was administered 2 ore before the test. Each value is the average of 7-1 3 tests.
  • tablet for oral administration containing :
  • silicified microcrystalline cellulose (filler) 32.656 mg
  • tablet for oral administration containing :
  • silicified microcrystalline cellulose (filler) 72.256 mg
  • tablet for oral administration containing:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet une association de principes actifs, c'est-à-dire d'un inhibiteur de la xanthine oxydase avec un ou plusieurs antagonistes du récepteur de l'angiotensine II, des compositions pharmaceutiques comprenant lesdits principes actifs, destinée à être utilisée dans un traitement thérapeutique chez des humains ou des animaux, et des procédés pour sa préparation.
PCT/EP2011/057438 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation WO2011141431A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2798573A CA2798573A1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du recepteur de l'angiotensine ii et son utilisation
JP2013509533A JP2013526503A (ja) 2010-05-10 2011-05-09 キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用
SG2012082319A SG185474A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
CN2011800232573A CN103037861A (zh) 2010-05-10 2011-05-09 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途
MX2012013054A MX2012013054A (es) 2010-05-10 2011-05-09 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso.
BR112012028887A BR112012028887A2 (pt) 2010-05-10 2011-05-09 associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos
AU2011252151A AU2011252151A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
NZ603414A NZ603414A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
US13/697,066 US20130131128A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
KR1020127032188A KR20130101447A (ko) 2010-05-10 2011-05-09 크산틴 옥시다아제 억제제 및 안지오텐신 ⅱ 수용체 길항제 및 이의 용도
EP11718734.4A EP2568982B1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation
EA201201528A EA201201528A1 (ru) 2010-05-10 2011-05-09 Комбинация ингибиторов ксантиноксидазы и антагонистов рецепторов ангиотензина-ii и ее применение
MA35430A MA34297B1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation
IL222927A IL222927A0 (en) 2010-05-10 2012-11-08 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
ZA2012/09295A ZA201209295B (en) 2010-05-10 2012-12-07 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
ITRM2010A000232 2010-05-10

Publications (1)

Publication Number Publication Date
WO2011141431A1 true WO2011141431A1 (fr) 2011-11-17

Family

ID=42753377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/057438 WO2011141431A1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation

Country Status (23)

Country Link
US (1) US20130131128A1 (fr)
EP (1) EP2568982B1 (fr)
JP (1) JP2013526503A (fr)
KR (1) KR20130101447A (fr)
CN (1) CN103037861A (fr)
AR (1) AR081376A1 (fr)
AU (1) AU2011252151A1 (fr)
BR (1) BR112012028887A2 (fr)
CA (1) CA2798573A1 (fr)
CL (1) CL2012003143A1 (fr)
CO (1) CO6640306A2 (fr)
EA (1) EA201201528A1 (fr)
EC (2) ECSP12012332A (fr)
IL (1) IL222927A0 (fr)
IT (1) IT1400311B1 (fr)
MA (1) MA34297B1 (fr)
MX (1) MX2012013054A (fr)
NZ (1) NZ603414A (fr)
PE (1) PE20130812A1 (fr)
SG (1) SG185474A1 (fr)
TW (1) TW201206432A (fr)
WO (1) WO2011141431A1 (fr)
ZA (1) ZA201209295B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503785A1 (fr) 1991-02-21 1992-09-16 Sankyo Company Limited Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique
EP0513379A1 (fr) 1990-11-30 1992-11-19 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
EP1020454A1 (fr) 1998-06-19 2000-07-19 Teijin Limited Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes
EP1336407A1 (fr) 2000-11-21 2003-08-20 Sankyo Company, Limited Compositions medicinales
WO2004060489A2 (fr) 2002-12-20 2004-07-22 Tap Pharmaceutical Products Inc. Traitement de l'insuffisance cardiaque chronique
EP1604664A1 (fr) 2003-01-31 2005-12-14 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
WO2007019153A2 (fr) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methodes de traitement de l'hypertension
WO2007062028A2 (fr) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Traitement d'allongement de l'intervalle qt et maladies associees
WO2008064015A1 (fr) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Procédés pour préserver la fonction rénale au moyen d'inhibiteurs de xanthine oxydoréductase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (fr) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Procedes et compositions permettant d'ameliorer la fonction endotheliale

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513379A1 (fr) 1990-11-30 1992-11-19 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
EP0503785A1 (fr) 1991-02-21 1992-09-16 Sankyo Company Limited Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique
EP1020454A1 (fr) 1998-06-19 2000-07-19 Teijin Limited Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes
EP1336407A1 (fr) 2000-11-21 2003-08-20 Sankyo Company, Limited Compositions medicinales
WO2004060489A2 (fr) 2002-12-20 2004-07-22 Tap Pharmaceutical Products Inc. Traitement de l'insuffisance cardiaque chronique
EP1604664A1 (fr) 2003-01-31 2005-12-14 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
WO2007019153A2 (fr) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methodes de traitement de l'hypertension
WO2007062028A2 (fr) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Traitement d'allongement de l'intervalle qt et maladies associees
WO2008064015A1 (fr) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Procédés pour préserver la fonction rénale au moyen d'inhibiteurs de xanthine oxydoréductase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOMALASKI JOHN S ET AL: "Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.", CURRENT RHEUMATOLOGY REPORTS, vol. 6, no. 3, June 2004 (2004-06-01), pages 240 - 247, XP002603882, ISSN: 1523-3774 *
GOODMAN G A ET AL: "GOODMAN and GILMAN'S The Pharmacological Basis of Therapeutics , (Angiotensin II receptor antagonists)", 1 January 2001, GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, NEW YORK : MCGRAW-HILL, US, ISBN: 978-0-07-135469-1, XP002604270 *
LEE S J ET AL: "New developments in clinically relevant mechanisms and treatment of hyperuricemia", CURRENT RHEUMATOLOGY REPORTS, vol. 8, no. 3, June 2006 (2006-06-01), US, pages 224 - 230, XP002604269 *
SORBERA L A ET AL: "TMX-67: Treatment of gout and hyperuricemia, xanthine oxidase inhibitor: TEI-6720", DRUGS OF THE FUTURE, vol. 26, no. 1, 1 January 2001 (2001-01-01), PROUS SCIENCE, ES, pages 32 - 38, XP002553641, ISSN: 0377-8282 *
TAKAHASHI S ET AL: "Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism", ANNALS OF THE RHEUMATIC DISEASES, vol. 62, no. 6, 1 June 2003 (2003-06-01), BRITISH MEDICAL ASSOCIATION, LONDON, GB, pages 572 - 575, XP008127491, ISSN: 0003-4967 *
WORTMANN R L: "Recent advances in the management of gout and hyperuricemia", CURRENT OPINION IN RHEUMATOLOGY, vol. 17, no. 3, 1 January 2005 (2005-01-01), CURRENT SCIENCE, LONDON, GB, pages 319 - 324, XP009125112, ISSN: 1040-8711, DOI: 10.1097/01.BOR.0000162060.25895.A5 *

Also Published As

Publication number Publication date
US20130131128A1 (en) 2013-05-23
AR081376A1 (es) 2012-08-29
CO6640306A2 (es) 2013-03-22
ITRM20100232A1 (it) 2011-11-11
IL222927A0 (en) 2012-12-31
SG185474A1 (en) 2012-12-28
JP2013526503A (ja) 2013-06-24
KR20130101447A (ko) 2013-09-13
TW201206432A (en) 2012-02-16
MA34297B1 (fr) 2013-06-01
PE20130812A1 (es) 2013-08-08
CN103037861A (zh) 2013-04-10
CA2798573A1 (fr) 2011-11-17
EA201201528A1 (ru) 2013-04-30
BR112012028887A2 (pt) 2016-07-26
ECSP12012332A (es) 2013-02-28
ECSP12012331A (es) 2013-02-28
ZA201209295B (en) 2013-08-28
AU2011252151A1 (en) 2012-11-29
EP2568982B1 (fr) 2014-04-02
NZ603414A (en) 2014-03-28
IT1400311B1 (it) 2013-05-24
MX2012013054A (es) 2013-03-05
CL2012003143A1 (es) 2013-06-21
EP2568982A1 (fr) 2013-03-20

Similar Documents

Publication Publication Date Title
DE69713890T2 (de) Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
US20050209288A1 (en) Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
JP3883205B2 (ja) アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
JP2007509055A (ja) ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の経口投与
WO2013018837A1 (fr) Agent d'amélioration de la fonction diastolique ventriculaire gauche
KR20150046125A (ko) Sglt2 저해약과 항고혈압약의 조합
WO2010009618A1 (fr) Composition pharmaceutique pour traiter l’hypertension et le syndrome métabolique et utilisation de celle-ci
WO2017006254A1 (fr) Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
JP7493048B2 (ja) 経口投与用の医薬組成物
EP2568982B1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation
CN115209919A (zh) 慢性心衰的治疗或预防方法
CN112638377A (zh) 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
EP2157089A1 (fr) Utilisations thérapeutiques de dérivés d'acide imidazol-5-carboxylique
WO2011141419A1 (fr) Association de l'inhibiteur de la xanthine oxydase fébuxostat et de metformine et son utilisation
KR20090094287A (ko) 용출성이 개선된 의약 조성물
AU2002328569B9 (en) Medicinal compositions containing angiotensin II receptor antagonist
WO2011141381A1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du calcium et son utilisation
US20130116291A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
JP2008133229A (ja) 医薬組成物
TW201729801A (zh) 協同性醫藥組合物
JPH06211657A (ja) 尿酸排泄剤
KR20080026115A (ko) 1-(3-클로로페닐)-3-알킬파이퍼라진을 포함하는 식욕 이상치료용 약학 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180023257.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718734

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2798573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12012502198

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2012003143

Country of ref document: CL

Ref document number: 222927

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013509533

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 002151-2012

Country of ref document: PE

Ref document number: MX/A/2012/013054

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1201005878

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011252151

Country of ref document: AU

Date of ref document: 20110509

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10217/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: CR2012-000617

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20127032188

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201201528

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12223245

Country of ref document: CO

Ref document number: 2011718734

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13697066

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012028887

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012028887

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121112